EVE.AU EVE Health Group Limited

Consumer Defensive Capital Markets Australian Securities Exchange
0.0135 AUD
Close of Oct 31, 2026
0.0090 0.0320
Market cap
AUD 4.76M
P/E
-
P/B
1.21x
ROE
-47.9%
Dividend yield
-
Fundamental score
0.6/5

Ratios use the latest price and the fiscal year ending Jun 2026.

Is EVE.AU undervalued?

Graham number

The Graham number of EVE Health Group Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

EVE Health Group Limited fundamental analysis

2 of 18 checks passed

ROE 0/2

Low return on equity (-47.9%), below 10%.

ROA 0/1

Return on assets (-44.2%) is below the industry median (3.0%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (43.6%) is above the industry median (-3.8%).

Revenue Growth 0/2

Revenue shrank 20.9% a year over the past 3 years.

Leverage 2/2

Total assets are 1.1x equity, within a prudent level for a financial company.

Equity Growth 0/1

Shareholders' equity did not grow over the past 5 years.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (1.2x) is above the industry median (0.9x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

EVE Health Group Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About EVE Health Group Limited

EVE Health Group Limited, a life sciences and healthcare company, engages in the development and commercialization of pharmaceutical products in Australia. It operates in two segments, Meluka (Branded Wellness Consumer Products) and Nextract (Pharmaceutical Products and Intellectual Property). Its lead product is the Dyspro, a formulation developed to address dysmenorrhoea and Endometriosis Pain; and Libbo, an oral dissolving film for erectile dysfunction. The company also d…

Full company profile